Navigation Links
Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
Date:3/23/2011

National Kidney Foundation Young Investigator Award and the American Society of Nephrology Gottschalk Research Scholar Award. He investigates kidney repair in order to translate this knowledge into therapies for patients with kidney disease.

The Neo-Kidney Augment is Tengion's lead preclinical program and is intended to prevent or delay the need for dialysis or kidney transplant by increasing functional kidney mass in patients with advanced chronic kidney disease, a significant unmet medical need. Tengion has now published or presented consistently positive data on the effect of its approach on kidney function in four different animal models of chronic kidney disease, including in a canine model of kidney failure. By the end of 2011, Tengion intends to seek an initial regulatory interaction with FDA for the Neo-Kidney Augment program to clarify the path to clinical trials.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trial
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
2. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
3. Tengion Announces Second Closing of Series C Financing
4. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
5. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
6. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
7. Tengion Appoints A. Brian Davis Chief Financial Officer
8. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
9. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
10. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
11. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and SUMMERLAND, British Columbia , ... XON ), a leader in synthetic biology, ... acquire  Okanagan Specialty Fruits (OSF), the pioneering agricultural ... the world,s first non-browning apple. Through the acquisition, Intrexon ... that is more appetizing and convenient for consumers while ...
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited (ASX:BNO, ... DisrupTOR-1 trial of BNC105 in patients with metastatic renal ... Orlando, Florida . The data will be ... City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 as ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5
... New research at Rice University shows that tiny worlds may ... Pulickel Ajayan has packed an entire lithium ion energy storage ... the American Chemical Society journal Nano Letters . The ... can possibly get, and could be valuable as a rechargeable ...
... July 28, 2011 BioMed Realty Trust, Inc. ... signing of a new lease with BIND Biosciences, ... Cambridge, Massachusetts.  BIND Biosciences, a biopharmaceutical company developing ... approximately 32,800 square feet of laboratory and office ...
... 2011 TriLink BioTechnologies, Inc. (TriLink) and Lucigen Corporation ... a licensing agreement for the use of TriLink,s CleanAmp™ ... TriLink,s CleanAmp™ dNTPs are an innovative approach ... dNTPs in a PCR assay with CleanAmp™ dNTPs, a ...
Cached Biology Technology:Rice scientists build battery in a nanowire 2Rice scientists build battery in a nanowire 3BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property 2BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property 3BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property 4TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation 2
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... Research from the University of Southampton, which examines how dolphins ... for man-made sonar to detect targets, such as sea mines, ... observed to blow ,bubble nets, around schools of fish, which ... the dolphins to pick off. However, such bubble nets would ...
... to pass on their genes, southern dumpling squid engage in ... University of Melbourne researchers have found that this results in ... afterwards. The research provides new insight into the evolution ... that the energetic costs of mating have been shown to ...
... 2012   TREW Marketing today announced a ... in B2B technology industries get information and use different ... recent survey targeting engineers, scientists, and technologists, and addresses ... use of industry publications and social media. ...
Cached Biology News:Do dolphins think nonlinearly? 2Do dolphins think nonlinearly? 3Promiscuous squid fatigued after mating 2TREW Marketing Webcast Shows B2B Companies How to Reach Technical Audiences 2
... Agencourt offers quick turnaround sequencing of ... copy and high copy plasmids. Agencourt's world-class, ... million Phred20 bases per day. The ... Sequencing service are 24 48 hour ...
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
...
Biology Products: